Process for preparing carrier particles for dry powders for inhalation

Abstract

Carrier particles in which at least 60% of the surface is coated with magnesium stearate are useful for preparing dry powder formulations for inhalation.

1 . A process for the preparation of a carrier for powder pharmaceutical compositions for inhalation,
 said process comprising dry coating lactose particles having a mass diameter of 30 to 1000 microns with 0.1 to 1.3% by weight, based on the weight of the carrier, of magnesium stearate, to obtain lactose particles surface coated with said magnesium stearate in an extent of more than 60% of the surface of said lactose particles,   wherein said dry coating is carried out in a high shear mixer granulator based on friction behavior at a rotation speed equal of 500 r.p.m. to 2500 r.p.m.   
     
     
         2 . A process according to  claim 1 , wherein said high shear mixer granulator is the CYCLOMIX™ apparatus. 
     
     
         3 . A process according to  claim 1 , wherein said rotation speed is 1000 to 2000 r.p.m. 
     
     
         4 . A process according to  claim 2 , wherein said rotation speed is 1000 to 2000 r.p.m. 
     
     
         5 . A process according to  claim 1 , wherein said dry coating step is carried out for a time of 2 to 20 minutes. 
     
     
         6 . A process according to  claim 1 , wherein said dry coating step is carried out for a time of 5 to 15 minutes. 
     
     
         7 . A process according to  claim 1 , wherein at least 80% of the surface of said lactose particles is coated with said magnesium stearate. 
     
     
         8 . A process according to  claim 1 , wherein at least 90% of the surface of said lactose particles is coated with said magnesium stearate. 
     
     
         9 . Carrier particles for a dry powder pharmaceutical formulation, which are prepared by a process according to  claim 1 . 
     
     
         10 . Carrier particles according to  claim 9 , wherein said rotation speed is 1000 to 2000 r.p.m. 
     
     
         11 . A pharmaceutical composition in the form of a dry powder for inhalation, comprising carrier particles according to  claim 9  and one or more active ingredients. 
     
     
         12 . A pharmaceutical composition according to  claim 11 , wherein said active ingredient comprises at least one beta 2 -agonist selected from the group consisting of salmeterol, formoterol, milveterol, vilanterol, olodaterol, indacaterol, a salt thereof, and a solvate form thereof. 
     
     
         13 . A pharmaceutical composition according to  claim 11 , wherein said active ingredient comprises at least one anticholinergic selected from the group consisting of tiotropium bromide, ipratropium bromide, oxitropium bromide, oxybutynin chloride, aclidinium bromide, trospium chloride, glycopyrronium bromide, GSK 573719, and GSK 1160274. 
     
     
         14 . A pharmaceutical composition according  claim 11 , wherein said active ingredient comprises at least one corticosteroid selected from the group consisting of beclomethasone dipropionate, fluticasone propionate, fluticasone furoate, budesonide, and mometasone furoate. 
     
     
         15 . A pharmaceutical composition according to  claim 11 , wherein said active ingredient comprises a phosphodiesterase-inhibitor. 
     
     
         16 . A dry powder inhaler, containing a pharmaceutical composition according to  claim 11 . 
     
     
         17 . A method for the prevention and/or treatment of a respiratory, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to  claim 11 . 
     
     
         18 . A method according to  claim 17 , wherein said respiratory conditions is asthma, chronic obstructive pulmonary disease, or allergic rhinitis.